X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
female (74) 74
oncology (73) 73
middle aged (60) 60
adult (54) 54
breast cancer (52) 52
breast neoplasms - drug therapy (51) 51
aged (50) 50
index medicus (42) 42
breast neoplasms - pathology (34) 34
treatment outcome (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
chemotherapy (22) 22
cancer (19) 19
metastasis (16) 16
survival (16) 16
neoplasm metastasis (15) 15
paclitaxel - administration & dosage (15) 15
breast neoplasms - genetics (14) 14
therapy (14) 14
prognosis (13) 13
breast neoplasms - mortality (12) 12
trastuzumab (12) 12
trial (12) 12
aged, 80 and over (11) 11
article (11) 11
carcinoma (11) 11
cyclophosphamide - administration & dosage (11) 11
doxorubicin (11) 11
doxorubicin - administration & dosage (11) 11
fluorouracil - administration & dosage (11) 11
paclitaxel (11) 11
paclitaxel - therapeutic use (11) 11
antineoplastic agents, phytogenic - adverse effects (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
health aspects (10) 10
immunotherapy (10) 10
neoplasm staging (10) 10
survival analysis (10) 10
antineoplastic agents, phytogenic - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
breast neoplasms - metabolism (9) 9
cyclophosphamide (9) 9
disease-free survival (9) 9
dose-response relationship, drug (9) 9
drug administration schedule (9) 9
male (9) 9
paclitaxel - adverse effects (9) 9
research (9) 9
antineoplastic agents - therapeutic use (8) 8
cells (8) 8
infusions, intravenous (8) 8
metastatic breast cancer (8) 8
time factors (8) 8
toxicity (8) 8
tumors (8) 8
vinblastine - analogs & derivatives (8) 8
women (8) 8
adjuvant chemotherapy (7) 7
antineoplastic agents - adverse effects (7) 7
breast neoplasms - surgery (7) 7
care and treatment (7) 7
colony-stimulating factor (7) 7
expression (7) 7
neoadjuvant chemotherapy (7) 7
neoplasms - drug therapy (7) 7
prospective studies (7) 7
retrospective studies (7) 7
vinorelbine (7) 7
antigen (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents, phytogenic - administration & dosage (6) 6
biomarkers (6) 6
docetaxel (6) 6
drug therapy (6) 6
follow-up studies (6) 6
neoadjuvant therapy (6) 6
predictive value of tests (6) 6
risk (6) 6
risk factors (6) 6
vinblastine - administration & dosage (6) 6
abridged index medicus (5) 5
antibodies, monoclonal - administration & dosage (5) 5
antineoplastic agents, hormonal - therapeutic use (5) 5
brain metastases (5) 5
breast (5) 5
breast neoplasms - immunology (5) 5
breast neoplasms - therapy (5) 5
breast-cancer (5) 5
cancer vaccines (5) 5
cancer vaccines - therapeutic use (5) 5
combination (5) 5
combined modality therapy (5) 5
diagnosis (5) 5
doxorubicin - adverse effects (5) 5
erbb-2 protein (5) 5
gene expression profiling (5) 5
gene-expression profiles (5) 5
her2 (5) 5
maximum tolerated dose (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Nature Communications, ISSN 2041-1723, 06/2017, Volume 8, Issue 1, p. 15916
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen... 
PALBOCICLIB | APOPTOSIS | CELLS | OXIDATIVE STRESS | ADVANCED BREAST-CANCER | MULTIDISCIPLINARY SCIENCES | REGULATES AUTOPHAGY | LETROZOLE | G1 ARREST | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Cyclin-Dependent Kinase 4 - genetics | Humans | Cellular Senescence - drug effects | Cytoplasm - metabolism | Antineoplastic Agents - administration & dosage | Breast Neoplasms - physiopathology | Cyclin E - genetics | Autophagy - drug effects | Breast Neoplasms - metabolism | Female | Cytoplasm - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Mice, Nude | Retinoblastoma Protein - genetics | Cell Line, Tumor | Mice | Cyclin E - metabolism | Cell Cycle - drug effects | Cytoplasm - drug effects | Senescence | Deregulation | Estrogens | Estrogen | Estrogen receptors | Breast cancer | Autophagy | Machinery | Cyclin-dependent kinase 4 | Machinery and equipment | Inhibitors | Cell cycle | Xenografts | Biomarkers | Breast | Cyclin E | Inhibition | In vitro methods and tests | Phagocytosis | Tumors | Cancer
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2018, Volume 143, Issue 9, pp. 2126 - 2132
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1115 - 1123
BACKGROUND The 2013 testing guidelines for determining the human epidermal growth factor receptor 2 (HER2) status include new cutoff points for the... 
invasive breast cancer | Smith‐Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | equivocal human epidermal growth factor receptor 2 (HER2) results | prognostic significance of equivocal human epidermal growth factor receptor 2 (HER2) results | alternative chromosome 17 genes in determining human epidermal growth factor receptor 2 (HER2) status | Smith-Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | prognostic significance of equivocal human epidermal | Smith-Magenis syndrome (SMS) and retinoic acid receptor alpha (RARA) genes as alternative chromosome 17 genes | IN-SITU HYBRIDIZATION | 17 COPY NUMBER | CENTROMERE | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | POLYSOMY | AMPLIFICATION | THERAPY | ONCOLOGY | HER2 STATUS | growth factor receptor 2 (HER2) results | AMERICAN-SOCIETY | Immunohistochemistry | Prognosis | Receptor, ErbB-2 - genetics | Humans | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Biomarkers, Tumor | Chromosomes, Human, Pair 17 - genetics | DNA Copy Number Variations | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Female | Breast Neoplasms - diagnosis | Cohort Studies | Usage | Breast cancer | Research | Reflexes | Testing | Enumeration | Copy number | Invasiveness | Genes | Fluorescence | Hazards | Regression analysis | Patients | Survival | ErbB-2 protein | Training | Confidence intervals | Epidermal growth factor | Fluorescence in situ hybridization | Breast | Clinical medicine | Probes | Chromosomes | Retinoic acid | Chromosome 17 | Cancer
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 28, pp. 4316 - 4323
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2015, Volume 21, Issue 9, pp. 1975 - 1977
In this phase I pharmacokinetic study of ABI-007, which was published in the May 1, 2002, issue of Clinical Cancer Research, Ibrahim and colleagues provided... 
SUPPRESSOR-CELLS | ONCOLOGY | NAB-PACLITAXEL | CANCER | CHEMOTHERAPY | Anniversaries and Special Events | Nanoparticles - therapeutic use | Humans | Albumin-Bound Paclitaxel - pharmacology | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - administration & dosage | Drug Delivery Systems | Neoplasms - drug therapy
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2005, Volume 23, Issue 25, pp. 5983 - 5992
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2015, Volume 33, Issue 4, pp. 890 - 894
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2002, Volume 8, Issue 5, pp. 1038 - 1044
Journal Article